Funded Research

Origins and consequences of Persistent Low-Level HIV Viremia During Antiretroviral Therapy

Year

2025

Host institution

Simon Fraser University

Research location

BC Centre for Excellence in HIV/AIDS
Simon Fraser University – Burnaby Campus

Partner

Supervisor

Dr. Zabrina Brumme

CO-lEad

Anti-HIV medications stop the virus from replicating in the body, prolonging life and preserving health. But, these medications are not a cure. This is because HIV, like all retroviruses, can persist within cells called “HIV reservoirs”, which can reactivate at any time to produce virus. This is why anti-HIV medications must be taken for life.

While taking anti-HIV medications, some people experience something called “persistent low-level viremia” where HIV levels in blood suddenly become detectable for no obvious reason. Historically, this was attributed to difficulties in taking medication daily, or the development of HIV drug resistance, so doctors would try to resolve it by changing the medications. But, this would often fail to resolve the issue, causing great stress. Recently, a major discovery was made: that persistent-low-level viremia can originate from HIV reservoirs. Namely, these cells can make clonal copies of themselves, which reactivate to produce HIV. But, many questions remain, and these new discoveries also need to be translated into practice. I will study a unique cohort of people living with HIV using cutting-edge techniques to advance our understanding of the HIV reservoir and improve HIV clinical care.

Building research careers

Since 2001, we’ve supported over 3,000 BC health researchers to launch programs, drive innovations, and attract millions in new research investment.

View all funded research

Funded research